

Serial No. 09/091,605

Cancel claims 1-15, 18, 21, 22, 24-32, and 34-43 and add the following claims 44 through 69.

44. The method of Claim 19, wherein Val⁸-GLP-1(7-37)OH is delivered to lower airways of the patient.
45. The method of Claim 44, wherein Val⁸-GLP-1(7-37)OH is deposited in the alveoli.
46. The method of Claim 19, wherein Val⁸-GLP-1(7-37)OH is inhaled through the mouth of the patient.
47. The method of Claim 19, wherein Val⁸-GLP-1(7-37)OH is administered as a pharmaceutical formulation comprising the Val⁸-GLP-1(7-37)OH in a pharmaceutically acceptable carrier.
- B 48. The method of Claim 47, wherein the formulation is selected from the group consisting of a solution in an aqueous medium and a suspension in a non-aqueous medium.
49. The method of Claim 48, wherein the formulation is administered as an aerosol.
50. The method of Claim 47, wherein the formulation is in the form of a dry powder.
51. The method of Claim 47, wherein the Val⁸-GLP-1(7-37)OH has a particle size of less than about 10 microns MMAD.
52. The method of Claim 51, wherein the Val⁸-GLP-1(7-37)OH has a particle size of about 1 to about 5 microns MMAD.

Serial No. 09/091,605

RECEIVED

DEC 21 2000

TECH CENTER 1600-300

53. The method of Claim 52, wherein the Val⁸-GLP-1(7-37)OH has a particle size of about 2 to about 3 microns MMAD.
54. The method of Claim 19, wherein at least about 10% of the Val⁸-GLP-1(7-37)OH delivered is deposited in the lung.
55. The method of Claim 19, wherein the Val⁸-GLP-1(7-37)OH is delivered from an inhalation device suitable for pulmonary administration and capable of depositing the Val⁸-GLP-1(7-37)OH in the lungs of the patient.
56. The method of Claim 55, wherein the device is selected from the group consisting of a nebulizer, a metered-dose inhaler, a dry powder inhaler, and a sprayer.
57. The method of claim 56, wherein the device is a dry powder inhaler.
58. The method of Claim 23, wherein the Val⁸-GLP-1(7-37)OH is delivered from an inhalation device suitable for pulmonary administration and capable of depositing the Val⁸-GLP-1(7-37)OH in the lungs of the patient.
59. The method of Claim 58, wherein the device is a sprayer or dry powder inhaler.
60. The method of Claim 58, wherein an actuation of the device administers about 40 µg to about 4,000 µg of Val⁸-GLP-1(7-37)OH.
61. The method of Claim 60, wherein an actuation of the

B1
amt

device administers about 80 µg to about 2,000 µg of Val⁸-GLP-1(7-37)OH.

62. The method of Claim 61, wherein an actuation of the device administers about 160 µg to about 1,000 µg of Val⁸-GLP-1(7-37)OH.

63. The method of claim 62, wherein an actuation of the device administers about 320 µg to about 500 µg of Val⁸-GLP-1(7-37)OH.

64. The method of Claim 33, wherein the Val⁸-GLP-1(7-37)OH is delivered from an inhalation device suitable for pulmonary administration and capable of depositing the Val⁸-GLP-1(7-37)OH in the lungs of the patient.

65. The method of Claim 64, wherein the device is a sprayer or dry powder inhaler.

66. The method of Claim 64, wherein an actuation of the device administers about 40 µg to about 4,000 µg of Val⁸-GLP-1(7-37)OH.

67. The method of Claim 66, wherein an actuation of the device administers about 80 µg to about 2,000 µg of Val⁸-GLP-1(7-37)OH.

68. The method of Claim 67, wherein an actuation of the device administers about 160 µg to about 1,000 µg of Val⁸-GLP-1(7-37)OH.

69. The method of claim 68, wherein an actuation of the device administers about 320 µg to about 500 µg of Val⁸-GLP-1(7-37)OH.

B1
cont